imatinib mesylate has been researched along with Shock in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Finkelman, F; Hogan, SP; Koleske, AJ; Noah, T; Waggoner, L; Wu, D; Yamani, A | 1 |
| Asada, N; Asakura, H; Koseki, M; Matsue, K; Takeuchi, M; Uryu, H | 1 |
2 other study(ies) available for imatinib mesylate and Shock
| Article | Year |
|---|---|
The vascular endothelial specific IL-4 receptor alpha-ABL1 kinase signaling axis regulates the severity of IgE-mediated anaphylactic reactions.
Topics: Allergens; Anaphylaxis; Animals; Antibodies; Cell Line; Endothelium, Vascular; Female; Histamine; Humans; Imatinib Mesylate; Immunoglobulin E; Interleukin-4; Male; Mice, Inbred BALB C; Mice, Transgenic; Ovalbumin; Proto-Oncogene Proteins c-abl; Receptors, Interleukin-4; Shock | 2018 |
Successful combined use of tranexamic acid and unfractionated heparin for life-threatening bleeding associated with intravascular coagulation in a patient with chronic myelogenous leukemia in blast crisis.
Topics: Acute Disease; Adult; alpha-2-Antiplasmin; Antifibrinolytic Agents; Antineoplastic Agents; Antithrombin III; Benzamides; Blast Crisis; Blood Transfusion; Bone Marrow Transplantation; Colon; Colonic Diseases; Disseminated Intravascular Coagulation; Fibrinolysin; Gastrointestinal Hemorrhage; Genes, abl; Heparin; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Peptide Hydrolases; Piperazines; Pyrimidines; Shock; Tranexamic Acid; Transplantation, Homologous | 2007 |